Indaptus Therapeutics, Inc. Proceeds from Notes Payable
Indaptus Therapeutics, Inc. (INDP) reported Proceeds from Notes Payable of $5.71 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-13
- Indaptus Therapeutics, Inc. proceeds from notes payable for the quarter ending 2025-12-31 was $0.00.
- Indaptus Therapeutics, Inc. proceeds from notes payable for the quarter ending 2025-09-30 was $0.00.
- Indaptus Therapeutics, Inc. proceeds from notes payable for fiscal 2025 was $5.71M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $5.71M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.71M 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $5.71M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |